RLMD INVESTOR NEWS: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – RLMD NEW YORK, June 10, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Relmada...

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – RLMD NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Relmada...

Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market NEW YORK, NY--(Marketwired - April 02, 2015) - Relmada Therapeutics, Inc. (OTCQB: RLMD) has quite a busy 2015 ahead of it in the clinic. The pharmaceutical company has stepped up its work in a big...

Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs NEW YORK, NY--(Marketwired - October 29, 2014) - Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline,...